Skip to main navigation

Top Navigation

Publications
Newsroom
Investors
Blog
Careers
Contact Us

mRNA Technology
Modalities
Pipeline
- Clinical Trials
- Therapeutic Areas
Citizenship
- Corporate Responsibility
About Us

Video Library

IR Navigation

Overview
Stock Information
Corporate Governance
SEC Filings
Events & Presentations
Press Releases
Shareholder Resources
Perspectives and Statements

Submenu - Event & Presentation

Events & Presentations
Video Library

Video Library

Moderna and the Propionic Acidemia Foundation

mRNA-3704 and Methylmalonic Acidemia

Moderna’s Clinical Development Manufacturing Facility

How Moderna Makes and Delivers Personalized Cancer Vaccines

Stronger Together: A Community Effort to Support People with Rare Metabolic Disorders

New Manufacturing Site in Norwood, MA

Pursuing KRAS: Amplifying Checkpoint Inhibitors with mRNA Cancer Vaccines

The Potential of Moderna's mRNA Platform for Developing a Vaccine to Fight CMV

Delivering on the promise of mRNA therapies for rare diseases

Advancing mRNA-based personalized cancer vaccines – Tal Zaks, MD, PhD, Moderna CMO

Moderna Early Development Engine - October 2017

Moderna Mission - October 2017

Moderna Research Engine, Oct 2017

Moderna’s Digitization Building Blocks

Advantages of mRNA Vaccines

mRNA Technology
Modalities
Pipeline
Citizenship
About Us

Publications
Newsroom
Investors
Blog
Careers
Contact Us

Facebook
Twitter
Youtube
LinkedIn

Footer Menu - Bottom

Privacy Policy
Join our Mailing List
Terms of Use

×

You are now leaving investors.modernatx.com, a website provided by Moderna. This link will take you to a website to which this Privacy Policy does not apply. We encourage you to read the Privacy Policy of every website you visit. The content displayed on external websites is not controlled by Moderna, and Moderna assumes no responsibility for the information or statements on such external websites.

Continue